Hepatocyte growth factor enhances ovarian cancer cell invasion through downregulation of thrombospondin-1

Cancer Biology and Therapy

Volumn 9, Issue 2, 2010, Pages 79-87

  Wei, Wei ^a   Beihua, Kong ^a   Qifeng, Yang ^a   Xun, Qu ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Hepatocyte growth factor (HGF); Invasion; Ovarian cancer; Thrombospondin 1 (TSP 1)

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; GELATINASE B; SCATTER FACTOR; THROMBOSPONDIN 1; 1,3 BUTADIENE DERIVATIVE; HGF PROTEIN, HUMAN; MESSENGER RNA; NITRILE; RECOMBINANT PROTEIN; RNA; TUMOR PROTEIN;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL INVASION; CELL STIMULATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INDUCTION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; OVARY CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ADENOCARCINOMA; BIOSYNTHESIS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; SECRETION; TUMOR CELL LINE;

ADENOCARCINOMA; BUTADIENES; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NITRILES; OVARIAN NEOPLASMS; RECOMBINANT PROTEINS; RNA, MESSENGER; RNA, NEOPLASM; THROMBOSPONDIN 1; TRANSFECTION;

EID: 75749083670     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.2.10280     Document Type: Article

References (62)

1. Maughan K. Specific keynote: in the shadow of illness-supporting women with ovarian cancer. Gynecol Oncol 2003; 88:129-33.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
3. Corps AN, Sowter HM, Smith SK. Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c-met. Int J Cancer 1997; 73:151-5.
4. Baykal C, Demirtas E, Al A, Ayhan A, Yuce K, Tulunay G, et al. Comparison of hepatocyte growth factor levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts. Int J Gynecol Cancer 2004; 14:152-6.
5. Walter-Yohrling J, Cao X, Callahan M, Weber W, Morgenbesser S, Madden SL, et al. Identification of genes expressed in malignant cells that promote invasion. Cancer Res 2003; 63:8939-47.
6. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342:440-3.
7. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002; 2:289-300.
8. Day RM, Cioce V, Breckenridge D, Castagnino P, Bottaro DP. Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis. Oncogene 1999; 18:3399-406.
9. Comoglio PM. Pathway specificity for Met signalling. Nat Cell Biol 2001; 3:161-2.
10. Fan S, Wang JA, Yuan RQ, Ma YX, Meng Q, Erdos MR, et al. BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene 1998; 16:3069-82.
11. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987; 327:239-42.
12. Scarpino S, Stoppacciaro A, Colarossi C, Cancellario F, Marzullo A, Marchesi M, et al. Hepatocyte growth factor (HGF) stimulates tumour invasiveness in papillary carcinoma of the thyroid. J Pathol 1999; 189:570-5.
13. Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 2003; 100:12718-23.
14. Scarpino S, Di Napoli A, Taraboletti G, Cancrini A, Ruco LP. Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells. J Pathol 2005; 205:50-6.
15. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 2003; 101:885-91.
16. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519-29.
17. Vasey PA. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer 2003; 89:23-8.
18. Parrott JA, Skinner MK. Expression and action of hepatocyte growth factor in human and bovine normal ovarian surface epithelium and ovarian cancer. Biol Reprod 2000; 62:491-500.
19. Sowter HM, Corps AN, Smith SK. Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells. Int J Cancer 1999; 83:476-80.
20. Wang X, Zhou Y, Kim HP, Song R, Zarnegar R, Ryter SW, et al. Hepatocyte growth factor protects against hypoxia/reoxygenation-induced apoptosis in endothelial cells. J Biol Chem 2004; 279:5237-43.
21. Bardella C, Dettori D, Olivero M, Coltella N, Mazzone M, Di Renzo MF. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo. Clin Cancer Res 2007; 13:2191-8.
22. Rasola A, Anguissola S, Ferrero N, Gramaglia D, Maffe A, Maggiora P, et al. Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. Cancer Res 2004; 64:1744-50.
23. Coltella N, Rasola A, Nano E, Bardella C, Fassetta M, Filigheddu N, et al. p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis. Int J Cancer 2006; 118:2981-90.
24. Kikuchi T, Maemondo M, Narumi K, Matsumoto K, Nakamura T, Nukiwa T. Tumor suppression induced by intratumor administration of adenovirus vector expressing NK4, a 4-kringle antagonist of hepatocyte growth factor, and naive dendritic cells. Blood 2002; 100:3950-9.
25. Saga Y, Mizukami H, Suzuki M, Urabe M, Kume A, Nakamura T, et al. Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival. Gene Ther 2001; 8:1450-5.
26. Wong AS, Roskelley CD, Pelech S, Miller D, Leung PC, Auersperg N. Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation. Exp Cell Res 2004; 299:248-56.
27. Maggiora P, Lorenzato A, Fracchioli S, Costa B, Castagnaro M, Arisio R, et al. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res 2003; 288:382-9.
28. Yabkowitz R, Mansfield PJ, Dixit VM, Suchard SJ. Motility of human carcinoma cells in response to thrombospondin: relationship to metastatic potential and thrombospondin structural domains. Cancer Res 1993; 53:378-87.
29. Roberts DD. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J 1996; 10:1183-91.
30. Iruela-Arispe ML, Luque A, Lee N. Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol 2004; 36:1070-8.
31. Sheibani N, Frazier WA. Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc Natl Acad Sci USA 1995; 92:6788-92.
32. Bleuel K, Popp S, Fusenig NE, Stanbridge EJ, Boukamp P. Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 over-expression through halted tumor vascularization. Proc Natl Acad Sci USA 1999; 96:2065-70.
33. Guo N, Zabrenetzky VS, Chandrasekaran L, Sipes JM, Lawler J, Krutzsch HC, et al. Differential roles of protein kinase C and pertussis toxin-sensitive G-binding proteins in modulation of melanoma cell proliferation and motility by thrombospondin 1. Cancer Res 1998; 58:3154-62.
34. Alvarez AA, Axelrod JR, Whitaker RS, Isner PD, Bentley RC, Dodge RK, et al. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis and survival in platinum-treated patients. Gynecol Oncol 2001; 82:273-8.
35. Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis and tumor progression. J Natl Cancer Inst 1997; 89:219-27.
36. Zabrenetzky V, Harris CC, Steeg PS, Roberts DD. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer 1994; 59:191-5.
37. Campbell SC, Volpert OV, Ivanovich M, Bouck NP. Molecular mediators of angiogenesis in bladder cancer. Cancer Res 1998; 58:1298-304.
38. Morandi V, Cherradi SE, Lambert S, Fauvel-Lafeve F, Legrand YJ, Legrand C. Proinflammatory cytokines (interleukin-1beta and tumor necrosis factor-alpha) downregulate synthesis and secretion of thrombospondin by human endothelial cells. J Cell Physiol 1994; 160:367-77.
39. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996; 69:135-74.
40. Ghoneim C, Soula-Rothhut M, Blanchevoye C, Martiny L, Antonicelli F, Rothhut B. Activating transcription factor-1-mediated hepatocyte growth factor-induced downregulation of thrombospondin-1 expression leads to thyroid cancer cell invasion. J Biol Chem 2007; 282:15490-7.
41. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circ Res 2003; 92:827-39.
42. Bar JK, Grelewski P, Popiela A, Noga L, Rabczynski J. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity. Gynecol Oncol 2004; 95:23-31.
43. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, et al. The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol 2002; 187:39-45.
44. Gong R, Rifai A, Tolbert EM, Centracchio JN, Dworkin LD. Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis. J Am Soc Nephrol 2003; 14:3047-60.
45. Zhou HY, Wong AS. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology 2006; 147:2557-66.
46. Trusolino L, Cavassa S, Angelini P, Ando M, Bertotti A, Comoglio PM, et al. HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB J 2000; 14:1629-40.
47. Hanzawa M, Shindoh M, Higashino F, Yasuda M, Inoue N, Hida K, et al. Hepatocyte growth factor upregulates E1AF that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes. Carcinogenesis 2000; 21:1079-85.
48. Bein K, Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 2000; 275:32167-73.
49. Qian X, Wang TN, Rothman VL, Nicosia RF, Tuszynski GP. Thrombospondin-1 modulates angiogenesis in vitro by upregulation of matrix metalloproteinase-9 in endothelial cells. Exp Cell Res 1997; 235:403-12.
50. Qian X, Rothman VL, Nicosia RF, Tuszynski GP. Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production. Pathol Oncol Res 2001; 7:251-9.
51. Ahmed N, Pansino F, Baker M, Rice G, Quinn M. Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. J Cell Biochem 2002; 84:675-86.
52. Lee KH, Hyun MS, Kim JR. Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis. Clin Exp Metastasis 2003; 20:499-505.
53. McCawley LJ, Li S, Wattenberg EV, Hudson LG. Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration. J Biol Chem 1999; 274:4347-53.
54. Gum R, Wang H, Lengyel E, Juarez J, Boyd D. Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. Oncogene 1997; 14:1481-93.
55. McCawley LJ, Li S, Benavidez M, Halbleib J, Wattenberg EV, Hudson LG. Elevation of intracellular cAMP inhibits growth factor-mediated matrix metalloproteinase-9 induction and keratinocyte migration. Mol Pharmacol 2000; 58:145-51.
56. Zhou HY, Wan KF, Ip CK, Wong CK, Mak NK, Lo KW, et al. Hepatocyte growth factor enhances proteolysis and invasiveness of human nasopharyngeal cancer cells through activation of PI3K and JNK. FEBS Lett 2008; 582:3415-22.
57. Zeigler ME, Chi Y, Schmidt T, Varani J. Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. J Cell Physiol 1999; 180:271-84.
58. Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 2003; 22:395-403.
59. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003; 104:527-32.
60. Suthiphongchai T, Promyart P, Virochrut S, Tohtong R, Wilairat P. Involvement of ERK1/2 in invasiveness and metastatic development of rat prostatic adenocarcinoma. Oncol Res 2003; 13:253-9.
61. Choo MK, Sakurai H, Koizumi K, Saiki I. Stimulation of cultured colon 26 cells with TNFalpha promotes lung metastasis through the extracellular signal-regulated kinase pathway. Cancer Lett 2005; 230:47-56.
62. Liu Z, Klominek J. Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors. Thorax 2003; 58:198-203.